ArticleMolecular and clinical oncology2017
Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients.
Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Protective Effect of Silymarin Against Paclitaxel-Induced Cardiotoxicity.Food science & nutrition · 2026Article
- Cytarabine induces cachexia with lipid malabsorption via zippering the junctions of lacteal in murine small intestine.Journal of lipid research · 2023Article
- Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells.Discover oncology · 2022Article
- High prevalence of overweight/obesity and dyslipidemia in patients with intracranial germ cell tumors.Pituitary · 2022Article
- Massive hypertriglyceridemia associated with paclitaxel; a case report.Gynecologic oncology reports · 2022Article
- Myocardial Ischemia Related to Common Cancer Therapy-Prevention Insights.Life (Basel, Switzerland) · 2022Review
- Article
- Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma.Gynecologic oncology reports · 2020Article
- Effect of lipid metabolism disorder on liver function in patients with malignant tumors after chemotherapy: a case-control study.Lipids in health and disease · 2019Article
- The formation of giant plasma membrane vesicles enable new insights into the regulation of cholesterol efflux.Experimental cell research · 2018Article
- Cisplatin Induced Acute Myocardial Infarction and Dyslipidemia.Journal of clinical and diagnostic research : JCDR · 2017Article
- Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.Case reports in oncologyArticle
- Atherosclerosis, Ischemia, and Anticancer Drugs.Heart views : the official journal of the Gulf Heart AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel and cisplatin (TP) are common chemotherapeutic agents extensively used for treating lung and esophageal cancers. The present study reported three patients with transient hypertriglyceridemia (HTG) following TP chemotherapy. Serum triglyceride (TG) levels returned to baseline at chemotherapy intermission. No patient had any history of HTG or any evidence of pancreatitis or other complications of HTG. No regular elevation of any other serum lipids, including cholesterol, high-density lipoprotein and low-density lipoprotein, was observed. However, treatment of mice with TP decreased TG and slightly increased cholesterol. The findings of the present study suggested that TP chemotherapy results in transient dyslipidemia, and physicians must monitor TG levels during chemotherapy to avoid TG-associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.